University Medical Center Freiburg, Department of Hematology & Oncology, Freiburg, Germany.
Antimicrob Agents Chemother. 2010 Sep;54(9):4029-32. doi: 10.1128/AAC.00150-10. Epub 2010 Jun 14.
Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 microg/liter versus 1,125 microg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly.
质子泵抑制剂（PPI）埃索美拉唑的平行给药已被证明会降低健康志愿者中泊沙康唑的口服生物利用度。我们前瞻性地分析了来自血液病患者（n = 27）的血清样本（n = 59），这些患者正在接受泊沙康唑预防治疗。同时接受泮托拉唑治疗的患者的泊沙康唑水平明显低于未接受 PPI 治疗的患者（中位数水平分别为 630μg/l 和 1125μg/l）。这些结果表明，当同时给予泊沙康唑和泮托拉唑时，药物监测是相关的。
